[Antimutagenic hypoxen activity in vivo]

The antimutagen effect of the drug hypoxen, representing poly(2,5-dihydroxyphenylene)-4-thiosulfonic acid sodium salt, was studied by chromosome aberration assay in the bone marrow cells of C57BL/6 mice. Hypoxen (20 mg/kg, i.p.) administered simultaneously with dioxidine (300 mg/kg, i.p.) reduced genotoxicity of the latter compound by 35% over a time period of 24 h. Preliminary five-day administration of hypoxen (70 mg/kg, p.o.) did not decrease the dioxidine damage. The genoprotector activity of hypoxen upon interaperitoneal injection is more pronounced as compared to that of the reference drug sladex (aspartam).